Please enable Javascript
RLT-PSMA
Radioligand therapy prostate-specific membrane antigen
Advertisement
Novel Theranostic Radiopharmaceutical Detects Lesions in Patients With PSMA PET-Negative BCR Prostate Cancer
Zachary Bessette
Next-Generation Imaging
|
September 13, 2023
Results of the BOP trial have shown 64Cu SAR-Bombesin can detect lesions in BCR prostate cancer that is PSMA PET-negative.
Read More
SNMMI Issues Consensus Statement on Patient Selection, Appropriate Use of Lu-177 PSMA-617
Zachary Bessette
mCRPC
|
September 6, 2023
SNMMI convened an autonomous workgroup to review prospective phase 2/3 clinical trials that used 177Lu-PSMA-617.
Read More
Real-world Data Show Benefit of 177Lu PSMA in Patients With mCRPC
Emily Menendez
RLT-PSMA
|
August 31, 2023
A PSA decrease ≥30% after the first 2 cycles of 177Lu PSMA can serve as an early marker of response in clinical practice.
Read More
Flotufolastat F 18 Added to NCCN Clinical Practice Guidelines for Prostate Cancer
Zachary Bessette
RLT-PSMA
|
July 27, 2023
The National Comprehensive Cancer Network now includes POSLUMA in its clinical practice guidelines for prostate cancer.
Read More
PYTHON Trial Shows Higher Detection Rate of [18F]DCFPyL Compared With [18F]Fluoromethylcholine
Emily Menendez
RLT-PSMA
|
July 26, 2023
[18F]DCFPyL impacted patient management in 44% of patients vs 29% of patients who received [18F]fluoromethylcholine.
Read More
[177Lu]Lu-PSMA-617 Plus Standard of Care Versus Standard of Care Alone for Patients With mCRPC
Emily Menendez
RLT-PSMA
|
July 5, 2023
The VISION trial assigned patients to receive either [177Lu]Lu-PSMA-617 plus standard of care or standard of care alone.
Read More
The Efficacy of Enzalutamide for PSA Decline Prior to Lu-177 PSMA Therapy
Emily Menendez
SNMMI 2023
|
June 29, 2023
Patients treated with enzalutamide prior to Lu-PSMA therapy had higher mean SUV values before treatment with 18 F-DCFPyL.
Read More
Dual PSMA/FDG-PET/CT Versus PSMA-Only Analysis in Patients With mCRPC
Emily Menendez
SNMMI 2023
|
June 29, 2023
68Ga-PSMA-11 and FDG-PET/CT scans were compared with scans from the VISION trial to assess patient eligibility for Pluvicto.
Read More
PSMA PET/CT Impacts the Clinical Management Plans of Patients With Prostate Cancer and BCR
Emily Menendez
SNMMI 2023
|
June 29, 2023
The care management plans for several patients were changed after those patients underwent PSMA PET/CT.
Read More
Evaluating PSMA PET/CT Scans Using the AI-Based aPROMISE Platform
Emily Menendez
SNMMI 2023
|
June 27, 2023
A research team developed a study to implement aPROMISE for the evaluation of PSMA and FDG-PET/CT scans acquired before RLT.
Read More
Post-treatment Radiation Safety Precautions for Lutetium-177 Vipivotide Tetraxetan
Emily Menendez
SNMMI 2023
|
June 27, 2023
A team of researchers compiled optimized methods for post-treatment radiation precautions for patients receiving Pluvicto.
Read More
Identifying Genomic Features, Post-therapeutic Predictors of Response to Lu-177 PSMA-617 for mCRPC
Zachary Bessette
SNMMI 2023
|
June 27, 2023
New research identified genomic features and post-therapeutic SPECT/CT parameters as predictors of response to Pluvicto.
Read More
Comparing Blood-, Image-, and Whole-Body Skeleton-Based Bone Marrow Dosimetry in 177Lu-PSMA-617 Therapy
Zachary Bessette
SNMMI 2023
|
June 27, 2023
A study compared bone marrow dosimetry using three different methods for patients treated with 177Lu-PSMA-617.
Read More
Dr. Brian Helfand on the SPOTLIGHT Study: Recurrent Prostate Cancer Detection With 18F-rhPSMA-7.3
Brian Helfand, MD, PhD
RLT-PSMA
|
June 26, 2023
Dr. Brian Helfand details the purpose of 18F-rhPSMA-7.3 and how it compares to other PSMA PET radiopharmaceuticals.
View More
PROPELLER: Assessing a Novel Imaging Agent in Patients With Intermediate-, High-Risk Prostate Cancer
Zachary Bessette
ASCO 2023
|
June 2, 2023
64Cu-SAR-bisPSMA may be safe and effective for detecting PSMA-expressing lesions, and 200MBq may be the optimal dose.
Read More
POSLUMA Becomes First FDA-Approved Radiohybrid PSMA-Targeted PET Imaging Agent
Emily Menendez
Next-Generation Imaging
|
May 30, 2023
POSLUMA is a diagnostic imaging agent for the PET detection of PSMA-positive lesions in patients with prostate cancer.
Read More
Using CD46-Targeted 225Ac Alpha Particle Radioimmunotherapy to Treat Prostate Cancer
Emily Menendez
RLT-PSMA
|
May 4, 2023
Researchers developed an antibody-drug conjugate and immuno-PET agent based on the YS5 antibody for high CD46.
Read More
SPOTLIGHT Study Results: Novel PSMA PET Radiopharmaceutical Offers Low Bladder Activity
Emily Menendez
RLT-PSMA
|
May 1, 2023
Researchers found 18F-rhPSMA-7.3 to have a high affinity and potential for low bladder activity.
Read More
68Ga-PSMA PET/CT and Metastasis-Directed Therapy in Prostate Cancer
Emily Menendez
AUA 2023
|
April 28, 2023
When testing interaction with the use of MDT, patients with positive PSMA PET not receiving MDT had a higher risk of CR.
Read More
FDA Fast Tracks 177Lu-PNT2002 for Treatment of mCRPC
Zachary Bessette
mCRPC
|
April 24, 2023
The FDA has granted Fast Track designation to 177Lu-PNT2002 for the treatment of patients with mCRPC.
Read More
Load More
Advertisement
Advertisement
Advertisement